Solid reports another DMD gene therapy setback

Solid Biosciences Inc. (NASDAQ:SLDB) reported lower-than-expected microdystrophin protein levels in liver biopsies from the first three patients treated with its microdystrophin gene transfer therapy, SGT-001, in the Phase I/II IGNITE DMD trial to treat Duchenne muscular dystrophy.

In two patients treated with 5x1013 vg/kg SGT-001 -- the trial protocol's lowest dose -- three-month biopsy data showed that microdystrophin protein was undetectable via western blot, and detected

Read the full 656 word article

User Sign In